BÃ¶rje J Ljungberg

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4369118/publications.pdf

Version: 2024-02-01

250	18,507	23567 58	13771 129
papers	citations	h-index	g-index

255	255	255	17304
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Incidence trends in lung and bladder cancers in the Nordic Countries before and after the smoking epidemic. European Journal of Cancer Prevention, 2022, 31, 228-234.	1.3	9
2	Inflammatory response markers and survival prediction in patients with renal cell carcinoma. Scandinavian Journal of Urology, 2022, 56, 47-52.	1.0	3
3	Survival in bladder and upper urinary tract cancers in Finland and Sweden through 50 years. PLoS ONE, 2022, 17, e0261124.	2.5	4
4	2021 Updated European Association of Urology Guidelines on the Use of Adjuvant Pembrolizumab for Renal Cell Carcinoma. European Urology, 2022, 81, 134-137.	1.9	29
5	OUP accepted manuscript. International Journal of Epidemiology, 2022, , .	1.9	1
6	European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update. European Urology, 2022, 82, 399-410.	1.9	485
7	Clinical T1a Renal Cell Carcinoma, Not Always a Harmless Diseaseâ€"A National Register Study. European Urology Open Science, 2022, 39, 22-28.	0.4	7
8	Ilixadencel, a Cell-based Immune Primer, plus Sunitinib Versus Sunitinib Alone in Metastatic Renal Cell Carcinoma: A Randomized Phase 2 Study. European Urology Open Science, 2022, 40, 38-45.	0.4	5
9	Reply to Yongbao Wei, Ruochen Zhang, and Le Linâ€™s Letter to the Editor re: BÃ¶rje Ljungberg, Laurence Albiges, Yasmin Abu-Ghanem, et al. European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update. Eur Urol. 2022;82:e88. European Urology, 2022, 82, e111-e112.	1.9	7
10	Significance of PI3K signalling pathway in clear cell renal cell carcinoma in relation to VHL and HIF status. Journal of Clinical Pathology, 2021, 74, 216-222.	2.0	11
11	The Impact of Histological Subtype on the Incidence, Timing, and Patterns of Recurrence in Patients with Renal Cell Carcinoma After Surgeryâ€"Results from RECUR Consortium. European Urology Oncology, 2021, 4, 473-482.	5.4	33
12	Novel Liquid Biomarkers and Innovative Imaging for Kidney Cancer Diagnosis: What Can Be Implemented in Our Practice Today? A Systematic Review of the Literature. European Urology Oncology, 2021, 4, 22-41.	5.4	33
13	A tactile resonance sensor for prostate cancer detection â€“ evaluation on human prostate tissue. Biomedical Physics and Engineering Express, 2021, 7, 025017.	1.2	1
14	Outcome after resection of occult and non-occult lymph node metastases at the time of nephrectomy. World Journal of Urology, 2021, 39, 3377-3383.	2.2	5
15	Validation of data quality in the National Swedish Kidney Cancer Register. Scandinavian Journal of Urology, 2021, 55, 142-148.	1.0	7
16	Increased risk for renal cell carcinoma in end stage renal disease â€“ a population-based case-control study. Scandinavian Journal of Urology, 2021, 55, 209-214.	1.0	4
17	Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Nivolumab plus Cabozantinib Joins Immune Checkpoint Inhibition Combination Therapies for Treatment-naÃ¯ve Metastatic Clear-Cell Renal Cell Carcinoma. European Urology, 2021, 79, 339-342.	1.9	98
18	Pattern, timing and predictors of recurrence after surgical resection of chromophobe renal cell carcinoma. World Journal of Urology, 2021, 39, 3823-3831.	2.2	2

#	Article	IF	Citations
19	Should patients with lowâ€risk renal cell carcinoma be followed differently after nephronâ€sparing surgery vs radical nephrectomy?. BJU International, 2021, 128, 386-394.	2.5	5
20	Prevalence, Disease-free, and Overall Survival of Contemporary Patients With Renal Cell Carcinoma Eligible for Adjuvant Checkpoint Inhibitor Trials. Clinical Genitourinary Cancer, 2021, 19, e92-e99.	1.9	30
21	Soft Drink and Juice Consumption and Renal Cell Carcinoma Incidence and Mortality in the European Prospective Investigation into Cancer and Nutrition. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 1270-1274.	2.5	9
22	A psychometric evaluation of the Functional assessment of cancer therapyâ€"kidney symptom index (FKSI-19) among renal cell carcinoma patients suggesting an alternative two-factor structure. Quality of Life Research, 2021, 30, 2663-2670.	3.1	5
23	Incidence trends in bladder and lung cancers between Denmark, Finland and Sweden may implicate oral tobacco (snuff/snus) as a possible risk factor. BMC Cancer, 2021, 21, 604.	2.6	7
24	Patientâ€reported outcome measures of abdominal wall morbidity after flank incision for open partial nephrectomy. BJU International, 2021, 128, 497-503.	2.5	2
25	Progress in survival in renal cell carcinoma through 50 years evaluated in Finland and Sweden. PLoS ONE, 2021, 16, e0253236.	2.5	13
26	The blood metabolome of incident kidney cancer: A caseâ€"control study nested within the MetKid consortium. PLoS Medicine, 2021, 18, e1003786.	8.4	16
27	Radical Nephrectomy: The Widening Gap Between Evolution of Technique and Evidence. European Urology, 2021, 80, 440-441.	1.9	0
28	The 2021 Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibitorâ€"based Combination Therapies for Treatment-naive Metastatic Clear-cell Renal Cell Carcinoma Are Standard of Care. European Urology, 2021, 80, 393-397.	1.9	103
29	Risk Prediction for Renal Cell Carcinoma: Results from the European Prospective Investigation into Cancer and Nutrition (EPIC) Prospective Cohort Study. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 507-512.	2.5	6
30	Management of Sporadic Renal Angiomyolipomas: A Systematic Review of Available Evidence to Guide Recommendations from the European Association of Urology Renal Cell Carcinoma Guidelines Panel. European Urology Oncology, 2020, 3, 57-72.	5.4	62
31	Targeted therapy for metastatic renal cell carcinoma. The Cochrane Library, 2020, 2020, CD012796.	2.8	23
32	Combining epigenetic and clinicopathological variables improves specificity in prognostic prediction in clear cell renal cell carcinoma. Journal of Translational Medicine, 2020, 18, 435.	4.4	4
33	Survival advantage of upfront cytoreductive nephrectomy in patients with primary metastatic renal cell carcinoma compared with systemic and palliative treatments in a real-world setting. Scandinavian Journal of Urology, 2020, 54, 487-492.	1.0	5
34	European Association of Urology Guidelines Office Rapid Reaction Group: An Organisation-wide Collaborative Effort to Adapt the European Association of Urology Guidelines Recommendations to the Coronavirus Disease 2019 Era. European Urology, 2020, 78, 21-28.	1.9	239
35	The renal cell cancer database Sweden (RCCBaSe) â€" a new register-based resource for renal cell carcinoma research. Scandinavian Journal of Urology, 2020, 54, 235-240.	1.0	7
36	Menstrual Factors, Reproductive History, Hormone Use, and Urothelial Carcinoma Risk: A Prospective Study in the EPIC Cohort. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 1654-1664.	2.5	3

#	ARTICLE	IF	CITATIONS
37	Topographic distribution of first landing sites of lymphatic metastases from patients with renal cancer. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 521-525.	1.6	5
38	Limitations of Available Studies Prevent Reliable Comparison Between Tumour Ablation and Partial Nephrectomy for Patients with Localised Renal Masses: A Systematic Review from the European Association of Urology Renal Cell Cancer Guideline Panel. European Urology Oncology, 2020, 3, 433-452.	5.4	43
39	Imaging in Suspected Renal-Cell Carcinoma: Systematic Review. Clinical Genitourinary Cancer, 2019, 17, e345-e355.	1.9	39
40	Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibition Is the New Backbone in First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma. European Urology, 2019, 76, 151-156.	1.9	190
41	Interactions between TGF-Î² type I receptor and hypoxia-inducible factor-Î± mediates a synergistic crosstalk leading to poor prognosis for patients with clear cell renal cell carcinoma. Cell Cycle, 2019, 18, 2141-2156.	2.6	34
42	Sex specific associations in genome wide association analysis of renal cell carcinoma. European Journal of Human Genetics, 2019, 27, 1589-1598.	2.8	27
43	An in-vitro assay using human spermatozoa to detect toxicity of biologically active substances. Scientific Reports, 2019, 9, 14525.	3.3	5
44	Harnessing the Genomic Landscape of the Small Renal Mass to Guide Clinical Management. European Urology Focus, 2019, 5, 949-957.	3.1	9
45	Oneâ€carbon metabolism biomarkers and risk of urothelial cell carcinoma in the European prospective investigation into cancer and nutrition. International Journal of Cancer, 2019, 145, 2349-2359.	5.1	6
46	Safe Use of Immune Checkpoint Inhibitors in the Multidisciplinary Management of Urological Cancer: The European Association of Urology Position in 2019. European Urology, 2019, 76, 368-380.	1.9	48
47	Increased use of cross-sectional imaging for follow-up does not improve post-recurrence survival of surgically treated initially localized R.C.C.: results from a European multicenter database (R.E.C.U.R.). Scandinavian Journal of Urology, 2019, 53, 14-20.	1.0	15
48	Real-world cost-effectiveness of targeted therapy in metastatic renal cell carcinoma in Sweden: a population-based retrospective analysis . Cancer Management and Research, 2019, Volume 11, 1289-1297.	1.9	4
49	European Association of Urology Guidelines on Renal Cell Carcinoma: The 2019 Update. European Urology, 2019, 75, 799-810.	1.9	1,022
50	Sources of Frustration Among Patients Diagnosed With Renal Cell Carcinoma. Frontiers in Oncology, 2019, 9, 11.	2.8	11
51	Surgical Metastasectomy in Renal Cell Carcinoma: A Systematic Review. European Urology Oncology, 2019, 2, 141-149.	5.4	73
52	The influence of obesity-related factors in the etiology of renal cell carcinomaâ€"A mendelian randomization study. PLoS Medicine, 2019, 16, e1002724.	8.4	59
53	DNA methylation associates with survival in non-metastatic clear cell renal cell carcinoma. BMC Cancer, 2019, 19, 65.	2.6	21
54	Intensive Imaging-based Follow-up of Surgically Treated Localised Renal Cell Carcinoma Does Not Improve Post-recurrence Survival: Results from a European Multicentre Database (RECUR). European Urology, 2019, 75, 261-264.	1.9	30

#	Article	IF	Citations
55	Long-term Outcomes of Follow-up for Initially Localised Clear Cell Renal Cell Carcinoma: RECUR Database Analysis. European Urology Focus, 2019, 5, 857-866.	3.1	67
56	Association between occurrence of urinary bladder cancer and treatment with statin medication. Turkish Journal of Urology, 2019, 45, 97-102.	1.3	7
57	Occurrence of abdominal bulging and hernia after open partial nephrectomy: a retrospective cohort study. Scandinavian Journal of Urology, 2018, 52, 54-58.	1.0	7
58	Updated European Association of Urology Guidelines: Recommendations for the Treatment of First-line Metastatic Clear Cell Renal Cancer. European Urology, 2018, 73, 311-315.	1.9	138
59	Systematic Review of the Management of Local Kidney Cancer Relapse. European Urology Oncology, 2018, 1, 512-523.	5.4	30
60	Use of venous-thrombotic-embolic prophylaxis in patients undergoing surgery for renal tumors: a questionnaire survey in the Nordic countries (The NORENCA -2 study). Research and Reports in Urology, 2018, Volume 10, 181-187.	1.0	2
61	VHL status regulates transforming growth factor-Î² signaling pathways in renal cell carcinoma. Oncotarget, 2018, 9, 16297-16310.	1.8	12
62	A Joint Statement from the European Association of Urology Renal Cell Cancer Guidelines Panel and the International Kidney Cancer Coalition: The Rejection of Ipilimumab and Nivolumab for Renal Cancer by the Committee for Medicinal Products for Human Use Does not Change Evidence-based Guideline Recommendations. European Urology, 2018, 74, 849-851.	1.9	3
63	Updated European Association of Urology Guidelines for Cytoreductive Nephrectomy in Patients with Synchronous Metastatic Clear-cell Renal Cell Carcinoma. European Urology, 2018, 74, 805-809.	1.9	80
64	Preâ€diagnostic circulating insulinâ€like growth factorâ€I and bladder cancer risk in the European Prospective Investigation into Cancer and Nutrition. International Journal of Cancer, 2018, 143, 2351-2358.	5.1	18
65	Prostate cancer detection ex vivo combining Raman spectroscopy and tactile resonance technology. IFMBE Proceedings, 2018, , 193-196.	0.3	0
66	Changing Current Practice in Urology: Improving Guideline Development and Implementation Through Stakeholder Engagement. European Urology, 2017, 72, 161-163.	1.9	13
67	Evaluation of the diagnostic accuracy of UBC^{Â®} Rapid in bladder cancer: a Swedish multicentre study. Scandinavian Journal of Urology, 2017, 51, 293-300.	1.0	17
68	Second-look resection for primary stage T1 bladder cancer: a population-based study. Scandinavian Journal of Urology, 2017, 51, 301-307.	1.0	15
69	Overall survival in Swedish patients with renal cell carcinoma treated in the period 2002 to 2012: Update of the RENCOMP study with subgroup analysis of the synchronous metastatic and elderly populations. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 541.e15-541.e22.	1.6	21
70	Genome-wide association study identifies multiple risk loci for renal cell carcinoma. Nature Communications, 2017, 8, 15724.	12.8	106
71	Spinal analgesia improves surgical outcome after open nephrectomy for renal cell carcinoma: a randomized controlled study. Scandinavian Journal of Urology, 2017, 51, 277-281.	1.0	4
72	A Systematic Review and Meta-analysis Comparing the Effectiveness and Adverse Effects of Different Systemic Treatments for Non-clear Cell Renal Cell Carcinoma. European Urology, 2017, 71, 426-436.	1.9	123

#	ARTICLE	IF	CITATIONS
73	Updated European Association of Urology Guidelines Regarding Adjuvant Therapy for Renal Cell Carcinoma. European Urology, 2017, 71, 719-722.	1.9	69
74	Reduced number of CD169⁺ macrophages in preâ€metastatic regional lymph nodes is associated with subsequent metastatic disease in an animal model and with poor outcome in prostate cancer patients. Prostate, 2017, 77, 1468-1477.	2.3	42
75	Genetic Variants Related to Longer Telomere Length are Associated with Increased Risk of Renal Cell Carcinoma. European Urology, 2017, 72, 747-754.	1.9	39
76	Contemporary treatment of renal tumors: a questionnaire survey in the Nordic countries (the) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 622	1.0	9
77	Prostate Cancer Detection with a Tactile Resonance Sensorâ€"Measurement Considerations and Clinical Setup. Sensors, 2017, 17, 2453.	3.8	14
78	Reply to E. Jason Abel Letter to the Editor re: Lorenzo Marconi, Saeed Dabestani, Thomas B. Lam, et al. Systematic Review and Meta-analysis of Diagnostic Accuracy of Percutaneous Renal Tumour Biopsy. Eur Urol 2016;69:660â€"73. European Urology, 2016, 69, e119-e120.	1.9	5
79	Reply to Jae Heon Kim's Letter to the Editor re: Lorenzo Marconi, Saeed Dabestani, Thomas B. Lam, et al. Systematic Review and Meta-analysis of Diagnostic Accuracy of Percutaneous Renal Tumour Biopsy. Eur Urol 2016;69:660â€"73. European Urology, 2016, 70, e141-e142.	1.9	0
80	Author Reply. Urology, 2016, 93, 122-123.	1.0	0
81	Nephron Sparing Surgery Associated With Better Survival Than Radical Nephrectomy in Patients Treated for Unforeseen Benign Renal Tumors. Urology, 2016, 93, 117-123.	1.0	17
82	Gender-related differences in urothelial carcinoma of the bladder: a population-based study from the Swedish National Registry of Urinary Bladder Cancer. Scandinavian Journal of Urology, 2016, 50, 292-297.	1.0	31
83	The Role of Cytoreductive Nephrectomy: European Association of Urology Recommendations in 2016. European Urology, 2016, 70, 901-905.	1.9	36
84	European Association of Urology Guidelines for Clear Cell Renal Cancers That Are Resistant to Vascular Endothelial Growth Factor Receptorâ€"Targeted Therapy. European Urology, 2016, 70, 705-706.	1.9	34
85	Renal cell carcinoma. World Journal of Urology, 2016, 34, 1051-1052.	2.2	3
86	Impact of quality indicators on adherence to National and European guidelines for renal cell carcinoma. Scandinavian Journal of Urology, 2016, 50, 2-8.	1.0	20
87	Comparing Everolimus to Sunitinib in Nonâ€"clear-cell Renal Cell Carcinoma. European Urology, 2016, 69, 875-876.	1.9	6
88	DNA methylation status defines clinicopathological parameters including survival for patients with clear cell renal cell carcinoma (ccRCC). Tumor Biology, 2016, 37, 10219-10228.	1.8	15
89	Renal cell carcinoma recurrences and metastases in primary non-metastatic patients: a population-based study. World Journal of Urology, 2016, 34, 1081-1086.	2.2	200
90	Identification of a novel susceptibility locus at 13q34 and refinement of the 20p12.2 region as a multi-signal locus associated with bladder cancer risk in individuals of European ancestry. Human Molecular Genetics, 2016, 25, 1203-1214.	2.9	38

#	Article	IF	Citations
91	Systematic Review of Surgical Management of Nonmetastatic Renal Cell Carcinoma with Vena Caval Thrombus. European Urology, 2016, 70, 265-280.	1.9	81
92	The radiogenomic risk score stratifies outcomes in a renal cell cancer phase 2 clinical trial. European Radiology, 2016, 26, 2798-2807.	4.5	33
93	Updated EAU Guidelines for Clear Cell Renal Cancer Patients Who Fail VEGF Targeted Therapy. European Urology, 2016, 69, 4-6.	1.9	85
94	Swedish National Registry of Urinary Bladder Cancer: No difference in relative survival over time despite more aggressive treatment. Scandinavian Journal of Urology, 2016, 50, 14-20.	1.0	20
95	Systematic Review and Meta-analysis of Diagnostic Accuracy of Percutaneous Renal Tumour Biopsy. European Urology, 2016, 69, 660-673.	1.9	412
96	Transforming growth factor-Î² promotes aggressiveness and invasion of clear cell renal cell carcinoma. Oncotarget, 2016, 7, 35917-35931.	1.8	38
97	Analysis of Heritability and Shared Heritability Based on Genome-Wide Association Studies for Thirteen Cancer Types. Journal of the National Cancer Institute, 2015, 107, djv279.	6.3	152
98	Alcohol consumption and the risk of renal cancers in the <scp>E</scp>uropean prospective investigation into cancer and nutrition (EPIC). International Journal of Cancer, 2015, 137, 1953-1966.	5.1	32
99	Specific Genomic Aberrations Predict Survival, But Low Mutation Rate in Cancer Hot Spots, in Clear Cell Renal Cell Carcinoma. Applied Immunohistochemistry and Molecular Morphology, 2015, 23, 334-342.	1.2	12
100	Cancer Characteristics and Current Treatments of Patients with Renal Cell Carcinoma in Sweden. BioMed Research International, 2015, 2015, 1-5.	1.9	19
101	EAU Guidelines on Renal Cell Carcinoma: 2014 Update. European Urology, 2015, 67, 913-924.	1.9	2,445
102	Local recurrence and progression of non-muscle-invasive bladder cancer in Sweden: a population-based follow-up study. Scandinavian Journal of Urology, 2015, 49, 290-295.	1.0	28
103	Meat and fish consumption and the risk of renal cell carcinoma in the <scp>E</scp>uropean prospective investigation into cancer and nutrition. International Journal of Cancer, 2015, 136, E423-31.	5.1	20
104	The Radiogenomic Risk Score: Construction of a Prognostic Quantitative, Noninvasive Image-based Molecular Assay for Renal Cell Carcinoma. Radiology, 2015, 277, 114-123.	7.3	61
105	TERT promoter mutations in clear cell renal cell carcinoma. International Journal of Cancer, 2015, 136, 2448-2452.	5.1	46
106	Use of bacillus Calmetteâ€“GuÃ©rin in stage T1 bladder cancer: Long-term observation of a population-based cohort. Scandinavian Journal of Urology, 2015, 49, 127-132.	1.0	11
107	The Axl-Regulating Tumor Suppressor miR-34a Is Increased in ccRCC but Does Not Correlate with Axl mRNA or Axl Protein Levels. PLoS ONE, 2015, 10, e0135991.	2.5	18
108	Overall survival (OS) in Swedish RCC patients treated 2000â€“2012: Update of the RENCOMP study.. Journal of Clinical Oncology, 2015, 33, 413-413.	1.6	0

#	ARTICLE	IF	CITATIONS
109	Circulating 25-Hydroxyvitamin D3 in Relation to Renal Cell Carcinoma Incidence and Survival in the EPIC Cohort. American Journal of Epidemiology, 2014, 180, 810-820.	3.4	27
110	Practice patterns for the surgical treatment of T1 renal cell carcinoma: A nationwide population-based register study. Scandinavian Journal of Urology, 2014, 48, 445-452.	1.0	18
111	Circulating Biomarkers of One-Carbon Metabolism in Relation to Renal Cell Carcinoma Incidence and Survival. Journal of the National Cancer Institute, 2014, 106, .	6.3	23
112	Urinary bladder cancer treated with radical cystectomy: Perioperative parameters and early complications prospectively registered in a national population-based database. Scandinavian Journal of Urology, 2014, 48, 334-340.	1.0	25
113	Imputation and subset-based association analysis across different cancer types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 5p15.33. Human Molecular Genetics, 2014, 23, 6616-6633.	2.9	90
114	Functional results after orthotopic bladder substitution: A prospective multicentre study comparing four types of neobladder. Scandinavian Journal of Urology, 2014, 48, 90-98.	1.0	8
115	Genome-wide interaction study of smoking and bladder cancer risk. Carcinogenesis, 2014, 35, 1737-1744.	2.8	50
116	Genome-wide association study identifies multiple loci associated with bladder cancer risk. Human Molecular Genetics, 2014, 23, 1387-1398.	2.9	137
117	Anthropometric measures and bladder cancer risk: A prospective study in the EPIC cohort. International Journal of Cancer, 2014, 135, 2918-2929.	5.1	26
118	The 19q12 Bladder Cancer GWAS Signal: Association with Cyclin E Function and Aggressive Disease. Cancer Research, 2014, 74, 5808-5818.	0.9	24
119	Local treatments for metastases of renal cell carcinoma: a systematic review. Lancet Oncology, The, 2014, 15, e549-e561.	10.7	265
120	The miR21/10b ratio as a prognostic marker in clear cell renal cell carcinoma. European Journal of Cancer, 2014, 50, 1758-1765.	2.8	63
121	Tumour characteristics and surgical treatment of renal cell carcinoma in Sweden 2005â€“2010: a population-based study from the National Swedish Kidney Cancer Register. Scandinavian Journal of Urology, 2014, 48, 231-238.	1.0	79
122	Macronutrient intake and risk of urothelial cell carcinoma in the European prospective investigation into cancer and nutrition. International Journal of Cancer, 2013, 132, 635-644.	5.1	34
123	Systematic Review of Adrenalectomy and Lymph Node Dissection in Locally Advanced Renal Cell Carcinoma. European Urology, 2013, 64, 799-810.	1.9	78
124	Re: Comparative Effectiveness for Survival and Renal Function of Partial and Radical Nephrectomy for Localized Renal Tumors: A Systematic Review and Meta-Analysis. Journal of Urology, 2013, 189, 1166-1168.	0.4	3
125	Impact of hospital volume on local recurrence and distant metastasis in bladder cancer patients treated with radical cystectomy in Sweden. Scandinavian Journal of Urology, 2013, 47, 483-490.	1.0	15
126	The Role of Metastasectomy in Renal Cell Carcinoma in the Era of Targeted Therapy. Current Urology Reports, 2013, 14, 19-25.	2.2	63

#	ARTICLE	IF	CITATIONS
127	Indentation loading response of a resonance sensorâ€"discriminating prostate cancer and normal tissue. Journal of Medical Engineering and Technology, 2013, 37, 416-423.	1.4	11
128	Osteopontin but not parathyroid hormone-related protein predicts prognosis in human renal cell carcinoma. Acta OncolÃ³gica, 2013, 52, 159-165.	1.8	10
129	N-acetyltransferase 2 Phenotype, Occupation, and Bladder Cancer Risk: Results from the EPIC Cohort. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 2055-2065.	2.5	31
130	CpG dinucleotide-specific hypermethylation of theTNS3gene promoter in human renal cell carcinoma. Epigenetics, 2013, 8, 739-747.	2.7	21
131	Telomere Length in Relation to Immunological Parameters in Patients with Renal Cell Carcinoma. PLoS ONE, 2013, 8, e55543.	2.5	25
132	Single Nucleotide Polymorphisms in the Wilmsâ€™ Tumour Gene 1 in Clear Cell Renal Cell Carcinoma. PLoS ONE, 2013, 8, e58396.	2.5	4
133	Metabolic Factors Associated with Risk of Renal Cell Carcinoma. PLoS ONE, 2013, 8, e57475.	2.5	75
134	Long-term follow-up after radical cystectomy with emphasis on complications and reoperations: A Swedish population-based survey. Scandinavian Journal of Urology and Nephrology, 2012, 46, 14-18.	1.4	19
135	Plasma carotenoids and vitamin C concentrations and risk of urothelial cell carcinoma in the European Prospective Investigation into Cancer and Nutrition. American Journal of Clinical Nutrition, 2012, 96, 902-910.	4.7	43
136	Systematic Review of Perioperative and Quality-of-life Outcomes Following Surgical Management of Localised Renal Cancer. European Urology, 2012, 62, 1097-1117.	1.9	210
137	Multidisciplinary management of metastatic renal cell carcinoma in the era of targeted therapies. Cancer Treatment Reviews, 2012, 38, 127-132.	7.7	9
138	Gene expression pattern of the epidermal growth factor receptor family and LRIG1 in renal cell carcinoma. BMC Research Notes, 2012, 5, 216.	1.4	17
139	Fruit and vegetable consumption and risk of aggressive and non-aggressive urothelial cell carcinomas in the European Prospective Investigation into Cancer and Nutrition. European Journal of Cancer, 2012, 48, 3267-3277.	2.8	26
140	A genome-wide association study identifies a novel susceptibility locus for renal cell carcinoma on 12p11.23. Human Molecular Genetics, 2012, 21, 456-462.	2.9	81
141	Systematic Review of Oncological Outcomes Following Surgical Management of Localised Renal Cancer. European Urology, 2012, 61, 972-993.	1.9	276
142	Sentinel node detection in renal cell carcinoma. A feasibility study for detection of tumourâ€draining lymph nodes. BJU International, 2012, 109, 1134-1139.	2.5	29
143	Nephron-Sparing Surgery Strategy: The Current Standard for the Treatment of Localised Renal Cell Carcinoma. European Urology Supplements, 2011, 10, e49-e51.	0.1	3
144	The Notch and TGF-Î² Signaling Pathways Contribute to the Aggressiveness of Clear Cell Renal Cell Carcinoma. PLoS ONE, 2011, 6, e23057.	2.5	56

#	ARTICLE	IF	CITATIONS
145	Defecation disturbances after cystectomy for urinary bladder cancer. BJU International, 2011, 108, 196-203.	2.5	16
146	Genome-wide association study of renal cell carcinoma identifies two susceptibility loci on 2p21 and 11q13.3. Nature Genetics, 2011, 43, 60-65.	21.4	220
147	Re: Can Partial Nephrectomy Preserve Renal Function and Modify Survival in Comparison with Radical Nephrectomy?. European Urology, 2011, 60, 595-596.	1.9	1
148	Metastatic Potential in Renal Cell Carcinomas â‰¥7cm: Swedish Kidney Cancer Quality Register Data. European Urology, 2011, 60, 975-982.	1.9	90
149	The Epidemiology of Renal Cell Carcinoma. European Urology, 2011, 60, 615-621.	1.9	817
150	Fluid intake and the risk of urothelial cell carcinomas in the European Prospective Investigation into Cancer and Nutrition (EPIC). International Journal of Cancer, 2011, 128, 2695-2708.	5.1	58
151	Variety in vegetable and fruit consumption and risk of bladder cancer in the European Prospective Investigation into Cancer and Nutrition. International Journal of Cancer, 2011, 128, 2971-2979.	5.1	26
152	Red Meat, Dietary Nitrosamines, and Heme Iron and Risk of Bladder Cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC). Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 555-559.	2.5	45
153	Contemporary epidemiology of renal cell carcinoma: perspectives of primary prevention. World Journal of Urology, 2010, 28, 247-252.	2.2	83
154	Hot topics in kidney cancer 2010. World Journal of Urology, 2010, 28, 245-246.	2.2	1
155	EAU Guidelines on Renal Cell Carcinoma: The 2010 Update. European Urology, 2010, 58, 398-406.	1.9	1,179
156	A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci. Nature Genetics, 2010, 42, 978-984.	21.4	493
157	Hygiene and urinary tract infections after cystectomy in 452 Swedish survivors of bladder cancer. BJU International, 2010, 105, 1107-1117.	2.5	10
158	Molecular Stratification of Clear Cell Renal Cell Carcinoma by Consensus Clustering Reveals Distinct Subtypes and Survival Patterns. Genes and Cancer, 2010, 1, 152-163.	1.9	283
159	A new nomogram predicting survival in renal cell carcinoma. Nature Reviews Urology, 2010, 7, 423-424.	3.8	6
160	Urinary diversion after cystectomy for bladder cancer: A population-based study in Sweden. Scandinavian Journal of Urology and Nephrology, 2010, 44, 69-75.	1.4	12
161	Preoperative carbohydrate drink improves postoperative quality of life after urological surgery: a randomized study. International Journal of Urological Nursing, 2009, 3, 64-68.	0.2	0
162	Tensin3 Is a Negative Regulator of Cell Migration and All Four Tensin Family Members Are Downregulated in Human Kidney Cancer. PLoS ONE, 2009, 4, e4350.	2.5	59

#	Article	IF	Citations
163	Alteration of Gene Expression Signatures of Cortical Differentiation and Wound Response in Lethal Clear Cell Renal Cell Carcinomas. PLoS ONE, 2009, 4, e6039.	2.5	15
164	Gas6 and the Receptor Tyrosine Kinase Axl in Clear Cell Renal Cell Carcinoma. PLoS ONE, 2009, 4, e7575.	2.5	39
165	Expression of Erythropoietin and Its Receptor in Human Renal Cell Carcinoma. Tumor Biology, 2009, 30, 86-92.	1.8	20
166	Hypoxia-inducible factor-2Î± mRNA expression in human renal cell carcinoma. Acta OncolÃ³gica, 2009, 48, 909-914.	1.8	13
167	Differential Expression of Axl and Gas6 in Renal Cell Carcinoma Reflecting Tumor Advancement and Survival. Clinical Cancer Research, 2009, 15, 4742-4749.	7.0	123
168	High-resolution DNA copy number and gene expression analyses distinguish chromophobe renal cell carcinomas and renal oncocytomas. BMC Cancer, 2009, 9, 152.	2.6	196
169	Diagnostic and Prognostic Molecular Markers for Renal Cell Carcinoma: A Critical Appraisal of the Current State of Research and Clinical Applicability. European Urology, 2009, 55, 851-863.	1.9	132
170	The PTEN regulator DJâ€1 is associated with hTERT expression in clear cell renal cell carcinoma. International Journal of Cancer, 2009, 125, 783-790.	5.1	52
171	A prospective analysis of the association between macronutrient intake and renal cell carcinoma in the European Prospective Investigation into Cancer and Nutrition. International Journal of Cancer, 2009, 125, 982-987.	5.1	32
172	Consumption of vegetables and fruit and the risk of bladder cancer in the European Prospective Investigation into Cancer and Nutrition. International Journal of Cancer, 2009, 125, 2643-2651.	5.1	42
173	CD 9 and vimentin distinguish clear cell from chromophobe renal cell carcinoma. BMC Clinical Pathology, 2009, 9, 9.	1.8	30
174	Telomere Length in Peripheral Blood Predicts Survival in Clear Cell Renal Cell Carcinoma. Cancer Research, 2009, 69, 2896-2901.	0.9	80
175	A population-based study of patterns of care for muscle-invasive bladder cancer in Sweden. Scandinavian Journal of Urology and Nephrology, 2009, 43, 271-276.	1.4	23
176	Downstaging and survival benefits of neoadjuvant radiotherapy before cystectomy for patients with invasive bladder carcinoma. Scandinavian Journal of Urology and Nephrology, 2009, 43, 293-299.	1.4	18
177	GuÃa del carcinoma de cÃ©lulas renales. Actas UrolÃ³gicas EspaÃ±olas, 2009, 33, 270-279.	0.7	5
178	Contemporary status of open nephron-sparing surgery in renal cell carcinoma. Archivio Italiano Di Urologia Andrologia, 2009, 81, 61-4.	0.8	2
179	Blood Pressure and Risk of Renal Cell Carcinoma in the European Prospective Investigation into Cancer and Nutrition. American Journal of Epidemiology, 2008, 167, 438-446.	3.4	170
180	Explanatory models for a tactile resonance sensor systemâ€"elastic and density-related variations of prostate tissuein vitro. Physiological Measurement, 2008, 29, 729-745.	2.1	25

#	Article	IF	Citations
181	Suppression of renal cell carcinoma growth by inhibition of Notch signaling in vitro and in vivo. Journal of Clinical Investigation, 2008, 118, 217-228.	8.2	157
182	Spatial variations in prostate tissue histology as measured by a tactile resonance sensor. Physiological Measurement, 2007, 28, 1267-1281.	2.1	9
183	Prognostic markers in renal cell carcinoma. Current Opinion in Urology, 2007, 17, 303-308.	1.8	79
184	Angiogenesis and other markers for prediction of survival in metastatic renal cell carcinoma. Scandinavian Journal of Urology and Nephrology, 2007, 41, 5-9.	1.4	12
185	Evaluation of CD31 (PECAM-1) Expression Using Tissue Microarray in Patients with Renal Cell Carcinoma. Tumor Biology, 2007, 28, 158-164.	1.8	24
186	Prognostic impact of carbonic anhydrase IX expression in human renal cell carcinoma. BJU International, 2007, 100, 556-560.	2.5	107
187	Glucose transporter-1 expression in renal cell carcinoma and its correlation with hypoxia inducible factor-1Î±. BJU International, 2007, 101, 071008070648007-???.	2.5	38
188	Reply to Andrea Minervini, Sergio Serni, Marco Carini and Claudio Di Cristofanoâ€™s Letter to the Editor re: Anders Lidgren, Ylva Hedberg, Kjell Grankvist, Torgny Rasmuson, Anders Bergh and BÃ¶rje Ljungberg. Hypoxia-Inducible Factor 1Î± Expression in Renal Cell Carcinoma Analyzed by Tissue Microarray. Eur Urol 2006;50:1272â€“7. European Urology, 2007, 51, 1452-1453.	1.9	0
189	Renal Cell Carcinoma Guideline. European Urology, 2007, 51, 1502-1510.	1.9	477
190	Reply to Giuseppe Di Lorenzoâ€™s Letter to the Editor re: BÃ¶rje Ljungberg, Damian C. Hanbury, Marcus A. Kuczyk, Axel S. Merseburger, Peter F.A. Mulders, Jean-Jaques Patard and Ioanel Sinescu. Renal Cell Cacinoma Guideline. Eur Urol 2007;51:1502â€“10. European Urology, 2007, 52, 928.	1.9	0
191	Expression Of Human Chorionic Gonadotropin Î²-Subunit Type I Genes Predicts Adverse Outcome In Renal Cell Carcinoma. Journal of Molecular Diagnostics, 2006, 8, 598-603.	2.8	15
192	Should patients with pathologic stage pT3 and pT4 RCC be reclassified to improve prognostic accuracy?. Nature Reviews Urology, 2006, 3, 136-137.	1.4	0
193	Endoglin (CD105) expression in human renal cell carcinoma. BJU International, 2006, 97, 706-710.	2.5	49
194	Different isoform patterns for vascular endothelial growth factor between clear cell and papillary renal cell carcinoma. BJU International, 2006, 97, 1102-1108.	2.5	32
195	Different vascular endothelial growth factor (VEGF), VEGF-receptor 1 and -2 mRNA expression profiles between clear cell and papillary renal cell carcinoma. BJU International, 2006, 98, 661-667.	2.5	51
196	Prostate tissue stiffness as measured with a resonance sensor system: a study on silicone and human prostate tissue in vitro. Medical and Biological Engineering and Computing, 2006, 44, 593-603.	2.8	54
197	Prostate cancer detection with an improved resonance sensor system: parameter evaluation in a silicone model and on human prostate tissue in vitro. Medical and Biological Engineering and Computing, 2006, 44, 1053-1059.	2.8	12
198	Hypoxia-Inducible Factor 1Î± Expression in Renal Cell Carcinoma Analyzed by Tissue Microarray. European Urology, 2006, 50, 1272-1277.	1.9	66

#	Article	IF	Citations
199	Body size and risk of renal cell carcinoma in the European Prospective Investigation into Cancer and Nutrition (EPIC). International Journal of Cancer, 2006, 118, 728-738.	5.1	173
200	Fruits and vegetables and renal cell carcinoma: Findings from the European prospective investigation into cancer and nutrition (EPIC). International Journal of Cancer, 2006, 118, 3133-3139.	5.1	73
201	Resonance sensor measurements of stiffness variations in prostate tissuein vitroâ€"a weighted tissue proportion model. Physiological Measurement, 2006, 27, 1373-1386.	2.1	45
202	Gene Expression Profiling Predicts Survival in Conventional Renal Cell Carcinoma. PLoS Medicine, 2005, 3, e13.	8.4	182
203	Adrenal metastasis in renal cell carcinoma: A recommendation for adjustment of the TNM staging system. Scandinavian Journal of Urology and Nephrology, 2005, 39, 277-282.	1.4	18
204	Parathyroid Hormone-Related Protein and Serum Calcium in Patients with Renal Cell Carcinoma. Tumor Biology, 2005, 26, 201-206.	1.8	21
205	The expression of hypoxia-inducible factor 1alpha is a favorable independent prognostic factor in renal cell carcinoma. Clinical Cancer Research, 2005, 11, 1129-35.	7.0	106
206	Serum insulin-like growth factor-1 is an independent predictor of prognosis in patients with renal cell carcinoma. Acta OncolÃ³gica, 2004, 43, 744-748.	1.8	59
207	Prognostic factors in renal cell carcinoma. Der Urologe, 2004, 43, 119-120.	2.0	12
208	Retinoblastoma protein in human renal cell carcinoma in relation to alterations in G1/S regulatory proteins. International Journal of Cancer, 2004, 109, 189-193.	5.1	23
209	ErbB4 is downregulated in renal cell carcinoma A quantitative RT-PCR and immunohistochemical analysis of the epidermal growth factor receptor family. Acta OncolÃ³gica, 2004, 43, 453-459.	1.8	23
210	Renal Cell Carcinoma. Scandinavian Journal of Surgery, 2004, 93, 87-87.	2.6	1
211	Tumour vascular endothelial growth factor (VEGF) mRNA in relation to serum VEGF protein levels and tumour progression in human renal cell carcinoma. Urological Research, 2003, 31, 335-340.	1.5	41
212	Status of pretreatment evaluation, treatment and followâ€up regimens for renal cell carcinoma in the Nordic countries. Scandinavian Journal of Urology and Nephrology, 2003, 37, 401-407.	1.4	7
213	Cyclin D3 Protein Content in Human Renal Cell Carcinoma in Relation to Cyclin D1 and Clinico-pathological Parameters. Acta OncolÃ³gica, 2002, 41, 175-181.	1.8	35
214	Cyclin E and p27 protein content in human renal cell carcinoma: Clinical outcome and associations with cyclin D. International Journal of Cancer, 2002, 102, 601-607.	5.1	42
215	Somatic mitochondrial DNA mutations in human chromophobe renal cell carcinomas. Genes Chromosomes and Cancer, 2002, 35, 256-260.	2.8	53
216	TUMOR ASSOCIATED TRYPSIN INHIBITOR AS A PROGNOSTIC FACTOR IN RENAL CELL CARCINOMA. Journal of Urology, 2001, 165, 959-962.	0.4	31

#	Article	IF	Citations
217	Factors of Importance for Prediction of Survival in Patients with Metastatic Renal Cell Carcinoma, Treated with or without Nephrectomy. Scandinavian Journal of Urology and Nephrology, 2000, 34, 246-251.	1.4	56
218	VASCULAR ENDOTHELIAL GROWTH FACTOR AS PROGNOSTIC FACTOR IN RENAL CELL CARCINOMA. Journal of Urology, 2000, 163, 343-347.	0.4	202
219	Clinical significance of nm23 expression in renal cell carcinoma. Urological Research, 1999, 27, 103-107.	1.5	5
220	Cyclin-D1 expression in human renal-cell carcinoma. , 1999, 84, 268-272.		43
221	Tumor-associated trypsin inhibitor in normal and malignant renal tissue and in serum of renal-cell carcinoma patients. , 1999, 83, 486-490.		39
222	Lack of genetic changes at specific genomic sites separates renal oncocytomas from renal cell carcinomas. Journal of Pathology, 1998, 184, 58-62.	4.5	36
223	Cellular Changes in Prostatic Carcinoma after Treatment with Orchidectomy, Estramustine Phosphate and Medroxyprogesterone Acetate. Scandinavian Journal of Urology and Nephrology, 1997, 31, 255-258.	1.4	3
224	The Heidelberg classification of renal cell tumours. Journal of Pathology, 1997, 183, 131-133.	4.5	1,142
225	Evaluation of five glycoprotein tumour markers (CEA, CA-50, CA-19-9, CA-125, CA-15-3) for the prognosis of renal-cell carcinoma. , 1997, 74, 233-236.		28
226	The Heidelberg classification of renal cell tumours. Journal of Pathology, 1997, 183, 131-133.	4.5	61
227	Evaluation of five glycoprotein tumour markers (CEA, CAâ€50, CAâ€19â€9, CAâ€125, CAâ€15â€3) for the prognosis of renalâ€cell carcinoma. International Journal of Cancer, 1997, 74, 233-236.	5.1	2
228	Predictive Value of DNA Ploidy in Bladder Cancer Treated with Preoperative Radiation Therapy and Cystectomy. Scandinavian Journal of Urology and Nephrology, 1996, 30, 281-285.	1.4	7
229	Proliferating Cell Nuclear Antigen Expression in Renal Cell Carcinoma. Scandinavian Journal of Urology and Nephrology, 1996, 30, 445-450.	1.4	7
230	Serum acute phase reactants and prognosis in renal cell carcinoma. Cancer, 1995, 76, 1435-1439.	4.1	58
231	Accuracy of Clinical Staging in Non-Seminomatous Testicular Cancerâ€"a Single Centre Experience of Retroperitoneal Lymph Node Dissection. Scandinavian Journal of Urology and Nephrology, 1995, 29, 501-506.	1.4	8
232	Vein Invasion in Renal Cell Carcinoma: Impact on Metastatic Behavior and Survival. Journal of Urology, 1995, 154, 1681-1684.	0.4	110
233	Proliferation of Human Renal Cell Carcinoma Studied with in Vivo Iododeoxyuridine Labelling and Immunohistochemistry. Scandinavian Journal of Urology and Nephrology, 1994, 28, 135-140.	1.4	6
234	Serum Î³-enolase and prognosis of patients with renal cell carcinoma. Cancer, 1993, 72, 1324-1328.	4.1	14

#	ARTICLE	IF	CITATIONS
235	Tumor-cell proliferation and prognosis in renal-cell carcinoma. International Journal of Cancer, 1993, 55, 566-570.	5.1	28
236	DNA fingerprinting of renal cell carcinoma with special reference to tumor heterogeneity. Genes Chromosomes and Cancer, 1993, 6, 86-91.	2.8	4
237	Multiple Renal Masses in Patients with Renal Cell Carcinoma: Diagnostic Pitfalls and Surgical Implications. Scandinavian Journal of Urology and Nephrology, 1992, 26, 367-371.	1.4	1
238	Erythropoietin in Renai Celi Carcinoma: Evaluation of Its Usefulness as a Tumor Marker. European Urology, 1992, 21, 160-163.	1.9	39
239	Flow Cytometric Deoxyribonucleic Acid Analysis in Stage I Renal Cell Carcinoma. Journal of Urology, 1991, 146, 697-699.	0.4	48
240	Genetic variation of haptoglobin and transferrin in relation to DNA content and stage in renal cell carcinoma. Cancer, 1989, 63, 1138-1142.	4.1	3
241	Effects of High Dose Medroxyprogesterone Acetate Treatment on Antithrombin III and other Plasma Proteins In Males With Renal Cell or Prostatic Carcinoma. Scandinavian Journal of Urology and Nephrology, 1989, 23, 11-14.	1.4	4
242	Deoxyribonucleic Acid Content and Medroxyprogesterone Acetate Treatment in Metastatic Renal Cell Carcinoma. Journal of Urology, 1989, 141, 1308-1310.	0.4	6
243	Renal cell carcinoma in tissue culture secretes nondialyzable product that stimulates bone resorption in organ-cultured mouse calvaria. Journal of Bone and Mineral Research, 1989, 4, 365-378.	2.8	6
244	Deoxyribonucleic acid content in metastatic renal cell carcinoma: Clinical implications. Journal of Surgical Oncology, 1988, 4, 165-168.	1.4	5
245	Renal Cell Carcinoma in a Solitary Kidney: Late Nephrectomy after 35 Years and Analysis of Tumor Deoxyribonucleic Acid Content. Journal of Urology, 1988, 139, 350-352.	0.4	11
246	A Comparison of Radiologic Methods in the Diagnosis of Renal Mass Lesions. Scandinavian Journal of Urology and Nephrology, 1988, 22, 187-196.	1.4	10
247	Inverted Papilloma with Intussusception of the Ureter. Scandinavian Journal of Urology and Nephrology, 1987, 21, 147-149.	1.4	8
248	Prognostic Value of Deoxyribonucleic Acid Content in Metastatic Renal Cell Carcinoma. Journal of Urology, 1986, 136, 801-804.	0.4	78
249	DNA content in renal cell carcinoma with reference to tumor heterogeneity. Cancer, 1985, 56, 503-508.	4.1	186
250	Targeted therapy for metastatic renal cell carcinoma. The Cochrane Library, 0, , .	2.8	12